Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 8
Submit an article Journal homepage
1,859
Views
381
CrossRef citations to date
0
Altmetric
Review

Colistin: an update on the antibiotic of the 21st century

Silpak Biswas CNRS-IRD, UMR 6236, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27, Boulevard Jean-Moulin, 13385 Marseille Cedex 05, France
,
Jean-Michel Brunel CNRS-IRD, UMR 6236, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27, Boulevard Jean-Moulin, 13385 Marseille Cedex 05, France
,
Jean-Christophe Dubus CNRS-IRD, UMR 6236, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27, Boulevard Jean-Moulin, 13385 Marseille Cedex 05, France
,
Martine Reynaud-Gaubert CNRS-IRD, UMR 6236, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27, Boulevard Jean-Moulin, 13385 Marseille Cedex 05, France
&
Jean-Marc Rolain CNRS-IRD, UMR 6236, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27, Boulevard Jean-Moulin, 13385 Marseille Cedex 05, France. [email protected]
Pages 917-934 | Published online: 10 Jan 2014

References

  • Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40(9), 1333–1341 (2005).
  • Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69(14), 1879–1901 (2009).
  • Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6(9), 589–601 (2006).
  • Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25(1), 11–25 (2005).
  • Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38(9), 1449–1459 (2004).
  • Karabinis A, Paramythiotou E, Mylona-Petropoulou D et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin. Infect. Dis. 38(1), e7–e9 (2004).
  • Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25(10), 1353–1364 (2005).
  • Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand. J. Infect. Dis. 37(2), 142–145 (2005).
  • Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J. Clin. Microbiol. 43(9), 4916–4917 (2005).
  • Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 21(3), 449–465 (2008).
  • Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19(6), 831–838 (1987).
  • Littlewood JM, Koch C, Lambert PA et al. A ten-year review of colomycin. Respir. Med. 94(7), 632–640 (2000).
  • Evans ME, Feola DJ, Rapp RP. PolymyxinB sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother. 33(9), 960–967 (1999).
  • Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther. 5(5), 811–821 (2007).
  • Nation RL, Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22(6), 535–543 (2009).
  • Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. J. Bacteriol. 54(1), 24 (1947).
  • Stansly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 81(1), 43–54 (1947).
  • Koyama Y. A new antibiotic ‘colistin’ produced by spore-forming soil bacteria. J.Antibiot. 3, 457–458 (1950).
  • Ross S, Puig JR, Zaremba EA. Colistin: some preliminary laboratory and clinical observations in specific gastroenteritis in infants and children. Antibiot. Annu. 7, 89–100 (1959).
  • Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50(6), 1953–1958 (2006).
  • Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr. Opin. Pharmacol. 11(5), 464–469 (2011).
  • Vaara M, Vaara T. Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature 303(5917), 526–528 (1983).
  • Nakajima K. Structure–activity relationship of colistins. Chem. Pharm. Bull. 15(8), 1219–1224 (1967).
  • Sakura N. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull. Chem. Soc. Jpn 77(10), 1915–1924 (2004).
  • Okimura K, Ohki K, Sato Y, Ohnishi K, Sakura N. Semi-synthesis of polymyxin B (2–10) and colistin (2–10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of α,γ-diaminobutyric acid residues. Chem. Pharm. Bull. 55(12), 1724–1730 (2007).
  • Vogler K, Studer RO. The chemistry of the polymyxin antibiotics. Experientia 22(6), 345–354 (1966).
  • Studer RO, Lergier W, Vogler K. Syntheses in the polymyxin series. 11. Synthesis of circulin A. Helv. Chim. Acta 49(2), 974–985 (1966).
  • de Visser PC, Kriek NM, van Hooft PA et al. Solid-phase synthesis of polymyxinB1 and analogues via a safety-catch approach. J. Pept. Res. 61(6), 298–306 (2003).
  • Tsubery H, Ofek I, Cohen S, Fridkin M. N-terminal modifications of polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 22(10), 1675–1681 (2001).
  • Chihara S. Chemical synthesis and characterization of n-fattyacyl mono-aminoacyl derivatives of colistin nonapeptide. Agric. Biol. Chem. 38, 1767–1777 (1974).
  • Okimura K. Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives. Bull. Chem. Soc. Jpn 80, 543–552 (2007).
  • Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res. 4(2), 138–146 (2006).
  • Curitis JR, Eastwood JB. Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis. Br. Med. J. 1(5590), 484–485 (1968).
  • Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit. Care Clin. 24(2), 377–391, x (2008).
  • Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann. Intensive Care 1(1), 30 (2011).
  • Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30(1), 143–151 (2008).
  • Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 53(8), 3430–3436 (2009).
  • Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 1(1), 14 (2011).
  • Couet W, Grégoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect. 18(1), 30–39 (2012).
  • Leroy P, Decolin D, Nicolas S, Archimbault P, Nicolas A. Residue determination of two co-administered antibacterial agents – cephalexin and colistin – in calf tissues using high-performance liquid chromatography and microbiological methods. J. Pharm. Biomed. Anal. 7(12), 1837–1846 (1989).
  • Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46(10), 3304–3307 (2002).
  • Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J. Pharm. Biomed. Anal. 49(3), 760–767 (2009).
  • Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography–tandem mass spectrometry. Antimicrob. Agents Chemother. 54(5), 1941–1948 (2010).
  • Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47(5), 1766–1770 (2003).
  • Ma Z, Wang J, Nation RL et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob. Agents Chemother. 53(7), 2857–2864 (2009).
  • Marchand S, Lamarche I, Gobin P, Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J. Antimicrob. Chemother. 65(8), 1753–1758 (2010).
  • Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 761(2), 167–175 (2001).
  • Imberti R, Cusato M, Villani P et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138(6), 1333–1339 (2010).
  • Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52(6), 987–992 (2003).
  • Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53(5), 837–840 (2004).
  • Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55(7), 3284–3294 (2011).
  • Dalfino L, Puntillo F, Mosca A et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin. Infect. Dis. 54(12), 1720–1726 (2012).
  • Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18(20), 4425–4430 (1979).
  • Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J.Bacteriol. 179(22), 7040–7045 (1997).
  • Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J. Bacteriol. 97(1), 448–452 (1969).
  • Conrad RS, Galanos C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob. Agents Chemother. 33(10), 1724–1728 (1989).
  • Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3(3), 238–250 (2005).
  • Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell. Mol. Life Sci. 66(23), 3821–3826 (2009).
  • Comite de l’Antibiogramme de la Societe Francaise de Microbiologie report 2003. Int. J. Antimicrob. Agents 21, 364–391 (2003).
  • Andrews JM; BSAC Working Party On Susceptibility Testing ft. BSAC standardized disc susceptibility testing method. J. Antimicrob. Chemother. 48(Suppl. 1), 43–57 (2001).
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, PA, USA (2008).
  • Moskowitz SM, Garber E, Chen Y et al. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J.Antimicrob. Chemother. 65(7), 1416–1423 (2010).
  • Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in vitro activity of colistin sulphomethate sodium. J. Antimicrob. Chemother. 39(2), 255–260 (1997).
  • Kuck NA. In vitro and in vivo activities of minocycline and other antibiotics against Acinetobacter (Herellea-Mima). Antimicrob. Agents Chemother. 9(3), 493–497 (1976).
  • Schülin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 49(2), 403–406 (2002).
  • Kosakai N, Oguri T. Distribution and changes of antibiotic susceptibility of genus Haemophilus (author’s transl). Jpn. J. Antibiot. 29(2), 159–166 (1976).
  • Thornsberry C, Baker CN, Kirven LA. Invitro activity of antimicrobial agents on Legionnaires disease bacterium. Antimicrob. Agents Chemother. 13(1), 78–80 (1978).
  • Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin. Microbiol. Infect. 12(4), 315–321 (2006).
  • Doern GV, Morse SA. Branhamella (Neisseria) catarrhalis: criteria for laboratory identification. J. Clin. Microbiol. 11(2), 193–195 (1980).
  • Glupczynski Y, Delmee M, Bruck C, Labbe M, Avesani V, Burette A. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur. J. Epidemiol. 4(2), 154–157 (1988).
  • García-Rodríguez JA, García-García MI, García-Sánchez E, García-Sánchez JE, Muñoz Bellido JL. In vitro activity of 16 antimicrobial agents against Helicobacter (Campylobacter) pylori. Enferm. Infecc. Microbiol. Clin. 7(10), 544–546 (1989).
  • Sidorczyk Z, Zähringer U, Rietschel ET. Chemical structure of the lipid A component of the lipopolysaccharide from a Proteus mirabilis Re-mutant. Eur. J. Biochem. 137(1–2), 15–22 (1983).
  • Schmoldt S, Latzin P, Heesemann J, Griese M, Imhof A, Hogardt M. Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response. J. Med. Microbiol. 55(Pt10), 1425–1433 (2006).
  • Daneshvar MI, Hollis DG, Steigerwalt AG et al. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J. Clin. Microbiol. 39(5), 1819–1826 (2001).
  • Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11(1), 57–80 (1998).
  • Alonso A, Martínez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41(5), 1140–1142 (1997).
  • Hase S, Reitschel ET. The chemical structure of the lipid A component of lipopolysaccharides from Chromobacterium violaceum NCTC 9694. Eur. J. Biochem. 75(1), 23–34 (1977).
  • Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58(9), 794–796 (2003).
  • Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45(3), 781–785 (2001).
  • Denton M, Kerr K, Mooney L et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 34(4), 257–261 (2002).
  • Nummila K, Kilpeläinen I, Zähringer U, Vaara M, Helander IM. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol. Microbiol. 16(2), 271–278 (1995).
  • Peterson AA, Fesik SW, McGroarty EJ. Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother. 31(2), 230–237 (1987).
  • Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50(9), 2946–2950 (2006).
  • Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 58(2), 138–144 (2009).
  • Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52(1), 351–352 (2008).
  • Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53(9), 3628–3634 (2009).
  • Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an invitro pharmacodynamic model. Antimicrob. Agents Chemother. 47(3), 905–909 (2003).
  • Poudyal A, Howden BP, Bell JM et al. Invitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62(6), 1311–1318 (2008).
  • Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 51(9), 3413–3415 (2007).
  • Owen RJ, Li J, Nation RL, Spelman D. Invitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J.Antimicrob. Chemother. 59(3), 473–477 (2007).
  • Breazeale SD, Ribeiro AA, McClerren AL, Raetz CR. A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-amino-4-deoxy-L-arabinose. Identification and function oF UDP-4-deoxy-4-formamido-L-arabinose. J. Biol. Chem. 280(14), 14154–14167 (2005).
  • Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635–700 (2002).
  • Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67(4), 593–656 (2003).
  • Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186(2), 575–579 (2004).
  • Lacour S, Bechet E, Cozzone AJ, Mijakovic I, Grangeasse C. Tyrosine phosphorylation of the UDP-glucose dehydrogenase of Escherichia coli is at the crossroads of colanic acid synthesis and polymyxin resistance. PLoS ONE 3(8), e3053 (2008).
  • Clements A, Tull D, Jenney AW et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J.Biol. Chem. 282(21), 15569–15577 (2007).
  • Lee H, Hsu FF, Turk J, Groisman EA. The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica. J. Bacteriol. 186(13), 4124–4133 (2004).
  • Helander IM, Kato Y, Kilpeläinen I et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur. J. Biochem. 237(1), 272–278 (1996).
  • Campos MA, Vargas MA, Regueiro V, Llompart CM, Albertí S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect. Immun. 72(12), 7107–7114 (2004).
  • Spinosa MR, Progida C, Talà A, Cogli L, Alifano P, Bucci C. The Neisseria meningitidis capsule is important for intracellular survival in human cells. Infect. Immun. 75(7), 3594–3603 (2007).
  • Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59(4), 786–790 (2007).
  • Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54(12), 4971–4977 (2010).
  • Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55(6), 3022–3024 (2011).
  • Beceiro A, Llobet E, Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55(7), 3370–3379 (2011).
  • Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents 37(6), 525–530 (2011).
  • Young ML, Bains M, Bell A, Hancock RE. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob. Agents Chemother. 36(11), 2566–2568 (1992).
  • Brown MR, Watkins WM. Low magnesium and phospholipid content of cell walls of Pseudomonas aeruginosa resistant to polymyxin. Nature 227(5265), 1360–1361 (1970).
  • Shand GH, Anwar H, Brown MR. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: effect of magnesium depletion. J. Antimicrob. Chemother. 22(6), 811–821 (1988).
  • Bell A, Bains M, Hancock RE. Pseudomonas aeruginosa outer membrane protein OprH: expression from the cloned gene and function in EDTA and gentamicin resistance. J. Bacteriol. 173(21), 6657–6664 (1991).
  • Macfarlane EL, Kwasnicka A, Ochs MM, Hancock RE. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol. Microbiol. 34(2), 305–316 (1999).
  • Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J.Antimicrob. Chemother. 45(4), 433–436 (2000).
  • Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 3(2), 255–264 (2001).
  • Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J. Antibiot. 33(12), 1551–1555 (1980).
  • Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE. Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(10), 4345–4351 (2009).
  • Fernández L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. Adaptive resistance to the ‘last hope’ antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54(8), 3372–3382 (2010).
  • Miller SI, Pulkkinen WS, Selsted ME, Mekalanos JJ. Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium. Infect. Immun. 58(11), 3706–3710 (1990).
  • Helander IM, Kilpeläinen I, Vaara M. Increased substitution of phosphate groups in lipopolysaccharides and lipid A of the polymyxin-resistant pmrA mutants of Salmonella typhimurium: a 31P-NMR study. Mol. Microbiol. 11(3), 481–487 (1994).
  • Groisman EA, Chiao E, Lipps CJ, Heffron F. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc. Natl Acad. Sci. USA 86(18), 7077–7081 (1989).
  • Sun S, Negrea A, Rhen M, Andersson DI. Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 53(6), 2298–2305 (2009).
  • López-Rojas R, Domínguez-Herrera J, McConnell MJ et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J. Infect. Dis. 203(4), 545–548 (2011).
  • López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J. Infect. Dis. 204(7), 1147–1148 (2011).
  • Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J.Infect. Dis. 204(7), 1146–1147 (2011).
  • Miller AK, Brannon MK, Stevens L et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 55(12), 5761–5769 (2011).
  • Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35(2), 194–199 (2010).
  • Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14(9), 816–827 (2008).
  • Furtado GH, d’Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30(4), 315–319 (2007).
  • Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J. Infect. 56(3), 185–190 (2008).
  • Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36(9), 1111–1118 (2003).
  • Rodriguez CH, Hernan RC, Bombicino K et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 65(2), 188–191 (2009).
  • Park YK, Jung SI, Park KH et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn. Microbiol. Infect. Dis. 64(1), 43–51 (2009).
  • Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med. 33(7), 1162–1167 (2007).
  • Cho YS, Yim H, Yang HT et al. Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. Infection (2011).
  • López-Alvarez B, Martín-Láez R, Fariñas MC, Paternina-Vidal B, García-Palomo JD, Vázquez-Barquero A. Multidrug-resistant Acinetobacter baumannii ventriculitis: successful treatment with intraventricular colistin. Acta Neurochir. (Wien) 151(11), 1465–1472 (2009).
  • Dalgic N, Ceylan Y, Sancar M et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Ann. Trop. Paediatr. 29(2), 141–147 (2009).
  • Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob. Agents Chemother. 51(6), 1905–1911 (2007).
  • Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir. Med. 103(5), 707–713 (2009).
  • Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med. 102(3), 407–412 (2008).
  • Kuo SC, Lee YT, Yang SP et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case–control study. Clin. Microbiol. Infect. 18(9), 870–876 (2011).
  • Ryan KJ, Schainuck LI, Hickman RO, Striker GE. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 207(11), 2099–2101 (1969).
  • Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72(6), 857–868 (1970).
  • Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP 25(11), 1168–1170 (1991).
  • Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N. Engl. J. Med. 266, 759–762 (1962).
  • Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol. 39(1), 15–20 (2005).
  • Etherington C. Urinary N-acetyl-â-D-glucosaminidase (NAG) in adults with CF-a marker of nephrotoxicity? J.Cyst. Fibros. 3(Suppl. 1), S49 (2004).
  • Hopper J Jr, Jawetz E, Hinman F Jr. Polymyxin B in chronic pyelonephritis: observations on the safety of the drug and on its influence on the renal infection. Am.J. Med. Sci. 225(4), 402–409 (1953).
  • Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 5, 1 (2005).
  • Kallel H, Bahloul M, Hergafi L et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int. J. Antimicrob. Agents 28(4), 366–369 (2006).
  • Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother. 49(8), 3136–3146 (2005).
  • Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7(5), R78–R83 (2003).
  • Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care 9(1), R53–R59 (2005).
  • Kwon JA, Lee JE, Huh W et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int. J. Antimicrob. Agents 35(5), 473–477 (2010).
  • Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48(12), 1724–1728 (2009).
  • Ko H, Jeon M, Choo E et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron. Clin. Pract. 117(3), c284–c288 (2011).
  • Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54(10), 4503–4505 (2010).
  • Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP 25, 1168–1170 (1991).
  • Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54(12), 5316–5322 (2010).
  • Aoki N, Tateda K, Kikuchi Y et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. JAntimicrob. Chemother. 63(3), 534–542 (2009).
  • Balaji V, Jeremiah SS, Baliga PR. Polymyxins: antimicrobial susceptibility concerns and therapeutic options. Indian J. Med. Microbiol. 29(3), 230–242 (2011).
  • White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40(8), 1914–1918 (1996).
  • J M. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Clinical Microbiology Procedures Handbook (2nd Edition). Garcia LS IH (Eds). ASM Press, Washington, DC, USA, 5.12.1–5.23 (2007).
  • Sopirala MM, Mangino JE, Gebreyes WA et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54(11), 4678–4683 (2010).
  • Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48(10), 3558–3562 (2010).
  • Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40(3), 117–120 (2001).
  • Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. JChemother. 15(3), 235–238 (2003).
  • Hogg GM, Barr JG, Webb CH. In vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 41(4), 494–495 (1998).
  • Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53(4), 274–278 (2006).
  • Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61(2), 417–420 (2008).
  • Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11, 109 (2011).
  • Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 45(5), 594–598 (2007).
  • Bolmstrom A, Karlsson A, Mills K et al. Quantifying synergy between colistin and rifampicin against carbapenem-resistant Acinetobacter with a novel combination gradient. Presented at: 45th Interscience Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology. Washington, DC, USA, Abstract E-797. 16–19 October 2005.
  • Sheng WH, Wang JT, Li SY et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70(3), 380–386 (2011).
  • Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. Agents 39(2), 105–114 (2012).
  • Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 39(2), 180–181 (2012).
  • Song JY, Lee J, Heo JY et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 32(3), 281–284 (2008).
  • Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53(5), 2133–2135 (2009).
  • Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob. Agents Chemother. 53(3), 1295–1296 (2009).
  • Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55(11), 5134–5142 (2011).
  • Wareham DW, Gordon NC, Hornsey M. Invitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 66(5), 1047–1051 (2011).
  • Sevillano E, Fernández E, Bustamante Z et al. Emergence and clonal dissemination of carbapenem-hydrolysing OXA-58-producing Acinetobacter baumannii isolates in Bolivia. J. Med. Microbiol. 61(Pt 1), 80–84 (2012).
  • Herrera ME, Mobilia LN, Posse GR. Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates. Rev. Argent. Microbiol. 43(2), 115–119 (2011).
  • McCracken M, Mataseje LF, Loo V et al.; Canadian Antimicrobial Resistance Alliance (CARA). Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 69(3), 335–341 (2011).
  • Singh S, Agarwal RK, Tiwari SC, Singh H. Antibiotic resistance pattern among the Salmonella isolated from human, animal and meat in India. Trop. Anim. Health Prod. 44(3), 665–674 (2012).
  • Japoni S, Japoni A, Farshad S, Ali AA, Jamalidoust M. Association between existence of integrons and multi-drug resistance in Acinetobacter isolated from patients in southern Iran. Pol. J. Microbiol. 60(2), 163–168 (2011).
  • Mammina C, Bonura C, Aleo A et al. Characterization of Acinetobacter baumannii from intensive care units and home care patients in Palermo, Italy. Clin. Microbiol. Infect. 17(11), E12–E15 (2011).
  • Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J.Chemother. 23(1), 13–16 (2011).
  • Netsvyetayeva I, Sikora M, Golas M et al. Acinetobacter baumannii multidrug-resistant strain occurrence in liver recipients with reference to other high-risk groups. Transplant. Proc. 43(8), 3116–3120 (2011).
  • Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J. Antimicrob. Chemother. 66(9), 2070–2074 (2011).
  • García-Castillo M, Del Campo R, Morosini MI et al. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J. Clin. Microbiol. 49(8), 2905–2910 (2011).
  • Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii. J. Med. Assoc. Thai. 94(Suppl. 3), S95–S100 (2011).
  • Maalej SM, Meziou MR, Rhimi FM, Hammami A. Comparison of disc diffusion, Etest and agar dilution for susceptibility testing of colistin against Enterobacteriaceae. Lett. Appl. Microbiol. 53(5), 546–551 (2011).
  • Neonakis IK, Samonis G, Messaritakis H et al. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin. Chemotherapy 56(6), 448–452 (2010).
  • Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Kapaskelis A, Samonis G. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int. J. Antimicrob. Agents 35(5), 497–499 (2010).
  • Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 65(1), 82–90 (2010).
  • Keen EF 3rd, Robinson BJ, Hospenthal DR et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 36(6), 819–825 (2010).
  • Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30(7), 666–671 (2009).
  • Gómez-Garcés JL, Aracil B, Gil Y, Burillo A. Susceptibility of 228 non-fermenting Gram-negative rods to tigecycline and six other antimicrobial drugs. J. Chemother. 21(3), 267–271 (2009).
  • Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int. J. Antimicrob. Agents 34(6), 580–584 (2009).
  • Eser OK, Ergin A, Hasçelik G. Antimicrobial resistance and existence of metallo-β-lactamase in Acinetobacter species isolated from adult patients. Mikrobiyol. Bul. 43(3), 383–390 (2009).
  • Walkty A, Decorby M, Nichol K, Mulvey MR, Hoban D, Zhanel G; Canadian Antimicrobial Resistance Alliance. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn. Microbiol. Infect. Dis. 61(2), 217–221 (2008).
  • Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-β-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J. Pathol. Microbiol. 51(2), 200–203 (2008).
  • Mezzatesta ML, Trovato G, Gona F et al. Invitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 7, 4 (2008).
  • Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. J. Med. Assoc. Thai. 91(Suppl. 3), S21–S27 (2008).
  • Fica CA. Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev. Chilena Infectol. 24, 360–367 (2007).
  • Sung H, Choi SJ, Yoo S, Kim MN. Invitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii. Korean J. Lab. Med. 27(2), 111–117 (2007).
  • Hawley JS, Murray CK, Griffith ME et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob. Agents Chemother. 51(1), 376–378 (2007).
  • Tognim MC, Gales AC, Penteado AP, Silbert S, Sader HS. Dissemination of IMP-1 metallo- β -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect. Control Hosp. Epidemiol. 27(7), 742–747 (2006).
  • Dobrewski R, Savov E, Bernards AT et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin. Microbiol. Infect. 12(11), 1135–1137 (2006).
  • Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50(9), 3166–3169 (2006).
  • Tan TY, Ng SY. The invitro activity of colistin in Gram-negative bacteria. Singapore Med. J. 47(7), 621–624 (2006).
  • Hill D, Rose B, Pajkos A et al. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 43(10), 5085–5090 (2005).
  • MacKenzie FM, Smith SV, Milne KE, Griffiths K, Legge J, Gould IM. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J. Cyst. Fibros. 3(3), 151–157 (2004).
  • Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39(1), 183–190 (2001).
  • Hejnar P, Kolár M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of β-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ. Palacki. Olomuc. Fac. Med. 142, 73–77 (1999).
  • Nicas TI, Hancock RE. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J. Bacteriol. 143(2), 872–878 (1980).
  • Vaara M, Vaara T, Jensen M et al. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett. 129(1), 145–149 (1981).
  • Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55(5), 2395–2397 (2011).
  • Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn. Microbiol. Infect. Dis. 63(2), 228–232 (2009).
  • Principe L, D’Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 8, 18 (2009).
  • López-Fabal F, Culebras E, Bonilla I, Gómez M, Picazo JJ. In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit. Rev. Esp. Quimioter. 21(3), 189–193 (2008).
  • Tan TY, Ng LS, Poh K. Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2. Diagn. Microbiol. Infect. Dis. 58(3), 357–361 (2007).
  • Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. Invitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27(3), 224–228 (2006).
  • Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 55(6), 954–957 (2005).
  • Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J. Chemother. 16(3), 282–287 (2004).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.